全球生物模擬市場 - 按應用（藥物開發、藥物發現）、最終用戶（製藥公司、生物技術公司、學術機構、研究實驗室）市場規模、份額和增長分析2023-2030行業預測

Global Biosimulation Market Size, Share, Growth Analysis, By Application(drug development, drug discovery), By End user(pharmaceutical and biotechnology companies, academic institutes and research laboratories) - Industry Forecast 2023-2030

出版日期: 2023年07月18日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2021 年全球生物模擬市場價值將達到 24 億美元，2022 年將達到 28.1 億美元。預計該市場在預測期內（2023-2030年）將以16.9%的複合年增長率擴張，並於2030年擴大至97.8億美元。

生物模擬是製藥和生物技術行業使用的最先進技術。包括計算機建模和模擬，以了解生物過程、藥物相互作用和疾病機制。這種創新方法使研究人員能夠預測候選藥物的結果並優化臨床試驗，從而降低成本並縮短上市時間。由於對個性化醫療的需求不斷增加以及藥物開發的複雜性不斷增加，生物模擬市場正在顯著增長。隨著技術的進步，生物模擬有望在改變藥物發現和藥物開發過程中發揮關鍵作用。

主要驅動力之一是醫療保健基礎設施的發展，通過提供昂貴的生物製劑的經濟高效的替代品，增加了對生物仿製藥的需求。此外，各種疾病患病率的上升以及對可獲得和負擔得起的治療方法的需求進一步推動了對生物仿製藥的需求。越來越多的專利到期藥物和正在進行的臨床試驗中令人鼓舞的結果也有助於市場的擴張。

生物模擬技術在藥物發現和開發中的使用缺乏標準化，並且採用不同的模型和技術來註冊和處理生物事件。生物模擬固有的複雜性給研究人員在存儲、操作和共享數據和模型方面帶來了挑戰。缺乏標準化方法阻礙了有效和可靠結果的產生，從而阻礙了生物模擬市場的增長。

本報告考察了全球生物模擬市場，並提供了市場概述、應用趨勢、最終用戶、地區以及進入市場的公司概況。

內容

執行摘要

母公司市場分析

市場規模

市場動態
驅動程序
機會
制約因素
任務

主要市場洞察

技術分析
價格分析
供應鏈分析
價值鏈分析
市場生態系統
知識產權分析
趨勢分析
啟動分析
原材料分析
創新矩陣
管道產品分析
宏觀經濟指標
熱門投資分析
關鍵成功因素
爭用程度

市場動態與展望

市場動態
驅動程序
機會
制約因素
任務
監管狀況
波特分析

全球生物模擬市場，按應用劃分

市場概況
藥物開發
藥物發現
其他

全球生物模擬市場，按最終用戶劃分

市場概況
製藥公司、生物技術公司
學術機構、研究機構
合同研究組織
其他

全球生物模擬市場（按地區）

市場概況
北美
歐洲
亞太地區
拉丁美洲
中東和非洲

競爭格局

主要公司簡介
Certara
Dassault Systemes SE
Simulations Plus Inc.
Schrodinger Inc.
Physiomics Plc
Advanced Chemistry Development Inc.
In silico biosciences Inc.
Genedata AG
Evidera Inc.
Leadscope Inc.
Insilico Biotechnology AG
Rhenovia Pharma SAS
Entelos Inc.
Biocomputing Platforms Ltd.
Rosa & Co. LLC
Genedata AG
OpenEye Scientific Software Inc.
Nexelis
Compugen Ltd.
Chemical Computing Group ULC

簡介目錄

Product Code: SQMIG35I2104

Market Insights

Bio simulation Market size was valued at USD 2.4 billion in 2021 and is poised to grow from USD 2.81 billion in 2022 to USD 9.78 billion by 2030, growing at a CAGR of 16.9% in the forecast period (2023-2030).

Biosimulation is a cutting-edge technology used in the pharmaceutical and biotechnology industries. It involves computer modeling and simulation to understand biological processes, drug interactions, and disease mechanisms. This innovative approach allows researchers to predict the outcomes of drug candidates and optimize clinical trials, reducing costs and time-to-market. The biosimulation market has witnessed substantial growth due to the increasing demand for personalized medicine and the rising complexity of drug development. As technology continues to advance, biosimulation is expected to play a pivotal role in revolutionizing drug discovery and development processes.

Top-down and bottom-up approaches were used to estimate and validate the size of bio simulation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biosimulation Market Segmental Analysis

The global biosimulation market is divided into three sections: offering type, application, and end user. The market is classified into two types of offerings: software and services. The software segment is divided into the following categories: PK/PD modelling and simulation, PBPK modelling and simulation, trial simulators, molecular modelling, and others. The Biosimulation Market is classified into three applications: drug discovery, drug development, and others. End users in the Biosimulation Market include contract research organisations, pharmaceutical and biotechnology companies, research institutes, regulatory institutes, and others. By region, the Biosimulation Market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver

One of the primary factors is the development of healthcare infrastructure, which has led to an increased demand for biosimilars as they offer cost-effective alternatives to expensive biologics. Additionally, the prevalence of various diseases has risen, creating a greater need for accessible and affordable treatments, further boosting the demand for biosimilars. The growing number of off-patent drugs and encouraging results from ongoing clinical trials also contribute to the market's expansion.

Restraints

The utilization of biosimulation technologies in drug discovery and development lacks standardization, employing diverse models and techniques to register and process biological events. The inherent complexity of biosimulation poses challenges for researchers in terms of data and model storage, manipulation, and sharing. The absence of standardized practices hampers the generation of effective and dependable results, impeding the growth of the biosimulation market.

Market Trends

A significant factor contributing to market expansion is the increasing occurrence of drug relapse cases attributed to drug resistance in various diseases like cancer, tuberculosis, and bacterial infections. This trend is propelling the demand for innovative solutions and technologies, including biosimulation, to address the challenges posed by drug resistance and improve treatment outcomes for patients.